Dissecting Structural Requirements of Leucinostatin A Derivatives for Antiprotozoal Activity and Mammalian Toxicity
Year: 2025
Type: article
Abstract: Lefleuganan, a clinical stage drug candidate for the treatment of cutaneous leishmaniasis, is a synthetic nonapeptide inspired by the natural antimicrobial peptide leucinostatin A, exhibiting excellent antiprotozoal activity in the low nM range. Lefleuganan shows strongly reduced acute toxicity, making it amenable for clinical use. Here, using a broad set of in vivo and in vitro measurements using purified enzymes, we find that leucinostatin A, but not lefleuganan, specifically targets the mitochondrial ATP synthase, inhibiting ATP synthesis by the human, bovine, and yeast enzyme in the nanomolar range. In a structure-activity relationship study covering the chemical space between the two compounds, hydroxyleucine at position 7 in leucinostatin A is identified as the key responsible moiety for specific ATP synthase inhibition and systemic toxicity. Our data suggest that efficient antiprotozoal activity of these class of compounds is mediated by efficient energetic uncoupling of negatively charged membranes.
Source: Journal of Medicinal Chemistry
Authors: Lukas Rimle, Dimanthi Pliatsika, Noëlle Arnold, Sandra Kurth, Marcel Kaiser, Pascal Mäser, Michael Kemmler, Michael Adams, Rainer Riedl, Christoph von Ballmoos
Language: English
Subfield: Microbiology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
Funders: National Science Foundation, Universität Basel, University of Bern, Inselspital, Universitätsspital Bern, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, UniBern Forschungsstiftung, Innosuisse - Schweizerische Agentur für Innovationsförderung, Zürcher Hochschule für Angewandte Wissenschaften
Awards: G2078108940, G3682716839, G7153587834
OpenAlex ID: W4407569293
